Results 161 to 170 of about 155,076 (257)

Multivariate phase‐dependent optimization of bioprocesses boosts performance and quality—Why timing (of exposure) matters

Biotechnology Progress, EarlyView.
Abstract Applying a single parameter set to describe complex mammalian kinetics often is too simplistic, as it fails to capture sensitive cell‐to‐environment interactions that may be exploited to optimize production performance. To resolve this time dependency, intra‐experimental parameter shifts as part of design of dynamic experiments (DoDE) can be ...
Samuel Kienzle, Lisa Junghans, Anja Wittmann, Stefan Wieschalka, Ralf Takors, Nicole Erika Radde, Beate Presser, Verena Nold   +7 more
wiley   +1 more source

β‐1,4‐galactosyltransferase 1 inhibitors modulate cellular N‐glycan profiles

Biotechnology Progress, EarlyView.
Graphical representation of the study workflow used to investigate the effects of known in vitro galactosyltransferase inhibitors on cell culture performance and recombinant IgG galactosylation. Abstract N‐glycosylation is a key post‐translational modification of proteins influencing their physicochemical properties as well as biological activity. This
Jaka Kranjc, Stane Pajk, Marko Anderluh, Anja Pišlar, Matjaž Brinc   +4 more
wiley   +1 more source

Fab N-Glycosylation in IgG: Implications in Physiological and Pathological Immune Regulation. [PDF]

Biomolecules
Chen S, Yu F, Huang B, Liang G, Xu J, Lin Y, Xu Q.   +6 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

N-Glycosylation of Band 3 is essential for the binding of Ganoderma lucidum immunomodulatory protein rLZ-8. [PDF]

Appl Microbiol Biotechnol
Diao W, Chen X, Liu D, Li S, Ma H, Guo H, Wang X.   +6 more
europepmc   +1 more source

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins

Biotechnology Progress, EarlyView.
Virus‐like particle vaccines displaying spike proteins from OC43, HKU1 A, and HKU1 B were evaluated in mice for their ability to elicit antibodies against the spike proteins from OC43, HKU1 A, HKU1 B, and HKU1 C. Abstract Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in ...
Peter J. Halfmann, Augustine Duffy, Alex Wee, Noah Anderson, Jackson Terrell, Yoshihiro Kawaoka, Ravi S. Kane   +6 more
wiley   +1 more source

Replication of 10 novel loci involved in human plasma protein N-glycosylation using MALDI-MS and UHPLC-FD data. [PDF]

Glycobiology
Timoshchuk A, Naber A, Slieker R, Soplenkova A, Maslov DE, Potapova NA, Nicolardi S, Elders PJM, Sijbrands EJG, Sharapov S, 't Hart LM, van Hoek M, Wuhrer M, Aulchenko YS.   +13 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

N-glycosylation modulates the inactivation kinetics of the Kv3.4 ion channel. [PDF]

iScience
Ranjan R, Logette E, Herzog M, Buchillier V, Scantamburlo E, Markram H.   +5 more
europepmc   +1 more source